Description du projet
Des nanoconstructions non immunogènes comme outil théranostique pour le traitement du cancer
Le projet TROJANANOHORSE, financé par le CER, entend développer des nanosystèmes thérapeutiques et diagnostiques (théranostiques) innovants, multifonctionnels, sûrs et non immunogènes, destinés au traitement du cancer et à l’imagerie cellulaire. Le concept du projet est basé sur un nanosystème récemment développé avec un noyau thérapeutiquement actif qui a été validé contre la leucémie. Le nanosystème repose sur une coque bicouche lipidique non immunogène dérivée d’une membrane de cellule cancéreuse autologue. Les objectifs du projet actuel comprennent notamment la construction du nanosystème théranostique suivie de l’évaluation de l’efficacité thérapeutique et de la spécificité du ciblage. L’étude testera la sécurité et la biodégradation de la nanoconstruction et étudiera les applications de bio-imagerie et de diagnostic, créant ainsi un outil théranostique complet.
Objectif
Nanomedicine tools for cancer treatment comprise many nanosized systems, so far developed with smart functions such as efficient drug delivery and cell targeting abilities. However they remain still undercharacterized in terms of immunogenicity, potential toxicity due to the materials itself or the unwanted release of drugs. To overcome these challenges this project aims to develop a new generation of multifunctional therapeutic and diagnostic (thus theranostics) nanosystems displaying non-immunogenicity, improved cancer treatment, cell imaging, and high safety for the hosting organism. The innovative concept behind this approach relies on a core-shell nanosystem with a therapeutically active core, i.e. a TrojaNanoHorse (TNH), here validated against leukaemia. The injectable TNH have a lipid bilayer shell derived from autologous cancer cell membrane, naturally non-immunogenic. The hemocompatibility, antithrombogenicity, and targeting ability with antibodies toward malignant blood cells will be proved during this project. Studies will show the zinc oxide nanocrystal core activation developing toxic reactive oxygen species (ROS) for cancer killing, and its green fluorescence emission. The whole TNH would go beyond the state-of-the-art due to its nature-derived biomimetic shell, absence of drugs, its safety and biodegrading fate, and green luminescent emissions for diagnosis. This project will also develop novel set-up for non-immunogenic therapy and diagnosis, impacting on future technology, new standardized protocols for nanomaterial safety assessment, and study chemical and biological mechanism of ROS development effects on cancer cell. Achieving the ultimate goal of a multifunctional TNH will require multidisciplinary expertise in chemistry, material science, biology, medicine and engineering, opening new horizons as nanomedicine tools for efficient cancer therapy with strong scientific, technological and socio-economic benefits.
Champ scientifique
- medical and health sciencesmedical biotechnologynanomedicine
- engineering and technologynanotechnologynano-materialsnanocrystals
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesbasic medicineimmunologyimmunotherapy
- medical and health sciencesclinical medicineoncologyleukemia
Programme(s)
Thème(s)
Régime de financement
ERC-STG - Starting GrantInstitution d’accueil
10129 Torino
Italie